Markets › LSE › 0J2O.L

Halozyme Therapeutics, Inc.

LSE:0J2O.LHealthcare

——At close · Market cap — · Next earnings Mon 2 Nov

USD billions	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	YoY
Revenue	0.3	0.4	0.7	0.8	1.0	1.4	+37.6%
Cost of revenue	0.0	0.1	0.2	0.3	0.2	0.3	+32.5%
Gross profit	0.2	0.4	0.5	0.6	0.8	1.1	+39.0%
Research & development	0.0	0.0	0.1	0.1	0.1	0.1	+3.1%
Selling, general & administrative	0.0	0.1	0.1	0.1	0.2	0.2	+25.3%
Selling & marketing	0.0	0.0	0.0	0.0	0.0	0.0	—
Operating expenses	0.1	0.1	0.2	0.2	0.2	0.3	+17.8%
Operating income	0.1	0.3	0.3	0.3	0.6	0.8	+48.0%
Interest expense	0.0	0.0	0.0	0.0	0.0	0.0	+0.2%
Interest income	0.0	0.0	0.0	0.0	0.0	0.0	—
Other income / expense	(0.0)	(0.0)	(0.0)	0.0	0.0	(0.3)	−6276.7%
Pre-tax income	0.1	0.2	0.2	0.3	0.6	0.5	−16.2%
Income tax	0.0	(0.2)	0.0	0.1	0.1	0.1	+32.7%
Net income	0.1	0.4	0.2	0.3	0.4	0.3	−28.6%
Discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	—
Other net income adjustments	0.0	0.0	0.0	0.0	0.0	0.0	—
EPS, basic (per share)	0.95	2.86	1.48	2.13	3.50	2.64	−24.6%
EPS, diluted (per share)	0.91	2.74	1.44	2.10	3.43	2.56	−25.4%
EBITDA	0.2	0.3	0.3	0.5	0.7	0.9	+37.7%
Depreciation & amortization	0.0	0.0	0.0	0.1	0.1	0.1	+8.3%
Weighted average shares (shares)	136,206,000	140,646,000	136,844,000	131,926,999	126,827,000	119,840,000	−5.5%
Weighted average diluted shares (shares)	141,463,000	146,796,000	140,608,000	134,197,000	129,424,000	123,904,000	−4.3%
Gross margin	83.8%	81.6%	72.4%	67.9%	77.3%	78.1%	+0.8 pts
Operating margin	53.9%	62.2%	43.8%	41.0%	54.3%	58.4%	+4.1 pts
Net margin	48.2%	90.8%	30.6%	34.0%	43.7%	22.7%	−21.0 pts